TaxTMI Login
AI OCR ✕Convert scanned orders, printed notices, PDFs and images into clean, searchable, editable text within seconds. Starting at 2 Credits/page
Try Now →Just a moment...
AI OCR ✕Convert scanned orders, printed notices, PDFs and images into clean, searchable, editable text within seconds. Starting at 2 Credits/page
Try Now →
Press 'Enter' to add multiple search terms. Rules for Better Search
Use comma for multiple locations.
---------------- For section wise search only -----------------
Accuracy Level ~ 90%
of 
Press 'Enter' after typing page number.
of Press 'Enter' after typing page number.
No Folders have been created
Are you sure you want to delete "My most important" ?
NOTE:
of Press 'Enter' after typing page number.
of Press 'Enter' after typing page number.
All Case Laws
of Press 'Enter' after typing page number.
of Press 'Enter' after typing page number.
All Case Laws
Note
Bookmark
Share
Don't have an account? Register Here
of Press 'Enter' after typing page number.
Issues: (i) Whether antisera used for blood grouping are classifiable under Heading 3002 or as blood-grouping reagents under Heading 3005; (ii) Whether purified protein derivative products used in diagnosis are classifiable under Heading 3002 or Heading 3005; (iii) Whether the products in Annexure B and Freunds Adjuvant are classifiable under Heading 3002 or Heading 3822, or require fresh consideration; and (iv) Whether the demand could be raised from the date of the classification list and whether the price was to be treated as cum-duty price.
Issue (i): Whether antisera used for blood grouping are classifiable under Heading 3002 or as blood-grouping reagents under Heading 3005.
Analysis: The heading for sera and antisera is not applied in isolation; the tariff structure and Chapter Note 3(e) specifically take blood-grouping reagents out of Heading 3002. The products, though sera in origin, are used for blood typing and agglutination tests, and the reasoning treats such use as bringing them within the expression blood-grouping reagents. The dictionary meaning of reagent was rejected as controlling, and the technical and tariff context was preferred.
Conclusion: The antisera used for blood grouping are classifiable under Heading 3005 and not under Heading 3002.
Issue (ii): Whether purified protein derivative products used in diagnosis are classifiable under Heading 3002 or Heading 3005.
Analysis: The products were traced to microbiological culture, but their final form was found to be a diagnostic reagent designed to be administered to the patient in measured doses. The distinction sought to be drawn between intradermal and other modes of administration was held immaterial, and multiple doses were treated as still satisfying the requirement of measured doses. On that basis the products fell within the tariff exclusion from Heading 3002 and within Heading 3005.
Conclusion: The PPD products are classifiable under Heading 3005.
Issue (iii): Whether the products in Annexure B and Freunds Adjuvant are classifiable under Heading 3002 or Heading 3822, or require fresh consideration.
Analysis: The goods in Annexure B were found to derive principally from blood fractions, sera, toxins, or similar biological material, and the reasoning rejected classification as miscellaneous chemical preparations merely because some carrier or component was synthetic. At the same time, the appellate forum declined to finally settle the precise classification in the form in which the matter had been argued, and directed de novo consideration by the adjudicating authority. Freunds Adjuvant was also placed in the same broader treatment and not finally decided on the existing record.
Conclusion: The classification dispute concerning Annexure B and Freunds Adjuvant was remanded for de novo consideration.
Issue (iv): Whether the demand could be raised from the date of the classification list and whether the price was to be treated as cum-duty price.
Analysis: The question of the relevant start date for differential duty depended on whether the earlier clearances were truly provisional and on the bonds, if any, filed under the assessment scheme, and the record was insufficient to finally determine that question. By contrast, the cum-duty issue was resolved in favour of treating the sale price as inclusive of duty once duty became payable on the goods.
Conclusion: The starting point for duty liability was left for reconsideration, while the cum-duty price direction was sustained.
Final Conclusion: The principal classification of the Annexure A antisera and PPD products was sustained under Heading 3005, the Annexure B classification and related quantification issues were sent back for fresh decision, and the cum-duty direction was upheld.
Ratio Decidendi: Where biological preparations are specifically used as blood-grouping reagents or diagnostic reagents designed to be administered to the patient, Chapter Note 3 to Chapter 30 excludes their classification under Heading 3002 and places them under the appropriate reagent heading.
TaxTMI 
TaxTMI 
